DE19675051I2 - Aminosaeurederivate - Google Patents

Aminosaeurederivate

Info

Publication number
DE19675051I2
DE19675051I2 DE1996175051 DE19675051C DE19675051I2 DE 19675051 I2 DE19675051 I2 DE 19675051I2 DE 1996175051 DE1996175051 DE 1996175051 DE 19675051 C DE19675051 C DE 19675051C DE 19675051 I2 DE19675051 I2 DE 19675051I2
Authority
DE
Germany
Prior art keywords
amino acid
acid derivatives
quinolylcarbonyl
prophylaxis
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE1996175051
Other languages
English (en)
Inventor
Martin Joseph Armstrong
Sally Redshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE19675051I2 publication Critical patent/DE19675051I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE1996175051 1989-12-11 1990-12-10 Aminosaeurederivate Active DE19675051I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (1)

Publication Number Publication Date
DE19675051I2 true DE19675051I2 (de) 2001-04-12

Family

ID=26296345

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69019481T Expired - Lifetime DE69019481T2 (de) 1989-12-11 1990-12-10 Aminosäurederivate.
DE1996175051 Active DE19675051I2 (de) 1989-12-11 1990-12-10 Aminosaeurederivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69019481T Expired - Lifetime DE69019481T2 (de) 1989-12-11 1990-12-10 Aminosäurederivate.

Country Status (48)

Country Link
US (1) US5196438A (de)
EP (1) EP0432695B1 (de)
JP (1) JP2807093B2 (de)
KR (1) KR970005912B1 (de)
CN (2) CN1066329C (de)
AT (1) ATE122661T1 (de)
AU (1) AU634319B2 (de)
BG (1) BG51452A3 (de)
BR (1) BR9006264A (de)
CA (1) CA2030433C (de)
CU (1) CU22305A3 (de)
CZ (1) CZ280558B6 (de)
DE (2) DE69019481T2 (de)
DK (1) DK0432695T3 (de)
DZ (1) DZ1467A1 (de)
EG (1) EG19722A (de)
ES (1) ES2072959T3 (de)
FI (2) FI100883B (de)
GB (2) GB8927913D0 (de)
GR (1) GR3017114T3 (de)
HK (1) HK129093A (de)
HR (1) HRP930341B1 (de)
HU (2) HU207298B (de)
ID (1) ID1018B (de)
IE (1) IE67523B1 (de)
IL (1) IL96550A (de)
IN (1) IN172553B (de)
IS (1) IS1803B (de)
LT (1) LT3682B (de)
LU (1) LU90014I2 (de)
LV (1) LV5738B4 (de)
MA (1) MA22014A1 (de)
MC (1) MC2195A1 (de)
MT (1) MTP1075B (de)
MW (1) MW8890A1 (de)
MX (1) MX173630B (de)
NL (1) NL970013I2 (de)
NO (1) NO176566C (de)
OA (1) OA09334A (de)
PL (1) PL165225B1 (de)
PT (1) PT96145B (de)
RO (1) RO107942B1 (de)
RU (1) RU2071470C1 (de)
SG (1) SG120493G (de)
SI (1) SI9012315B (de)
SK (1) SK280249B6 (de)
ZA (1) ZA909743B (de)
ZW (1) ZW17490A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DE69224703T2 (de) * 1991-11-08 1998-10-15 Merck & Co Inc HIV-Protease-Inhibitoren verwendbar in der AIDS-Behandlung
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
EP0560268B1 (de) * 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituierte Pipecoline-Säurederivate als HIV-Protease-Hemmer
EP1148050A1 (de) * 1992-05-21 2001-10-24 Monsanto Company Retrovirale Proteaseinhibitoren
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
KR100336699B1 (ko) 1992-08-25 2002-05-13 윌리암스 로저 에이 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
WO1994017096A1 (en) * 1993-01-17 1994-08-04 Schering Corporation Peptides having anti-hiv activity
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ES2125077T3 (es) 1993-07-15 1999-02-16 Hoffmann La Roche Procedimiento de obtencion de una n-tert-butilamida.
AU8074894A (en) * 1994-02-02 1995-08-21 Eli Lilly And Company Hiv protease inhibitors and intermediates
CN1146201A (zh) * 1994-03-07 1997-03-26 沃泰克斯药物股份有限公司 用作天冬氨酰蛋白酶抑制剂的磺胺衍生物
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
TR199701541T1 (xx) * 1995-06-06 1998-03-21 F.Hoffmann-La Roche Ag Proteinaz engelleyici ve tekli gliserid i�eren farmas�tik bile�im.
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP0861085B1 (de) 1995-11-13 2005-07-20 Vitaleech Bioscience N.V. Antivirale isolate von blutegeln
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ATE236880T1 (de) 1996-12-11 2003-04-15 Hoffmann La Roche Verfahren zur herstellung gemischter anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
AP1717A (en) 1998-06-19 2007-01-30 Vertex Pharma Sulfonamide inhibitors of aspartyl protease.
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
CN101361723B (zh) * 1999-06-04 2013-11-06 Abbvie公司 改进的药物制剂
AU6109500A (en) * 1999-07-20 2001-02-05 Merck & Co., Inc. Alpha-hydroxy-gamma-(((carbocyclic-or heterocyclic-substituted)amino)carbonyl)alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
EP1242426B1 (de) 1999-11-24 2007-10-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
ATE395049T1 (de) 2000-01-19 2008-05-15 Abbott Lab Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
AU2002359721A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
JP2005529953A (ja) * 2002-06-17 2005-10-06 サネシス ファーマシューティカルズ， インコーポレイテッド アスパルチルプロテアーゼインヒビター
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EA015349B1 (ru) * 2003-07-11 2011-06-30 Ф. Хоффманн-Ля Рош Аг Твёрдая разовая пероральная фармацевтическая дозированная форма саквинавирмезилата и способ её изготовления
EP1604662A1 (de) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidin-(2R)-carbonsäure-benzylamine-Derivate und verwandte Verbindungen als Dipeptidyl-Peptidase IV (DPP-IV) Inhibitoren zur Behandlung von Typ 2 Diabetes Mellitus
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
SG182228A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and uses thereof
EP2203420A1 (de) * 2007-09-25 2010-07-07 Merck Sharp & Dohme Corp. Hiv-proteasehemmer
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
NZ617066A (en) * 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
EP2671888A1 (de) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-zyklische Nucleosidphosphatanaloga
US8497383B2 (en) 2009-05-27 2013-07-30 Merck Sharp & Dohme Corp. HIV protease inhibitors
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
EP2392926A1 (de) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinbiomarker in HIV-infizierten Subjekten
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
WO2013105118A1 (en) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir
AU2013315833A1 (en) 2012-09-11 2015-03-05 Merck Canada Inc. HIV protease inhibitors
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP3083609B1 (de) 2013-12-19 2018-08-15 Merck Sharp & Dohme Corp. Hiv-proteasehemmer
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US11116774B2 (en) 2014-07-11 2021-09-14 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (en) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Optically active amino alcohol derivatives and process for their preparation
US4851387A (en) * 1986-10-14 1989-07-25 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Also Published As

Publication number Publication date
PL288201A1 (en) 1991-09-09
MC2195A1 (fr) 1992-10-05
IE67523B1 (en) 1996-04-03
PT96145B (pt) 1998-04-30
DZ1467A1 (fr) 2004-09-13
DE69019481T2 (de) 1995-11-09
HU207298B (en) 1993-03-29
CN1052482A (zh) 1991-06-26
EP0432695A2 (de) 1991-06-19
RO107942B1 (ro) 1994-01-31
US5196438A (en) 1993-03-23
GB2239016A (en) 1991-06-19
RU2071470C1 (ru) 1997-01-10
FI100883B (fi) 1998-03-13
MA22014A1 (fr) 1991-07-01
ATE122661T1 (de) 1995-06-15
CN1034805C (zh) 1997-05-07
IN172553B (de) 1993-09-25
MX23619A (es) 1993-10-01
ID1018B (id) 1996-10-18
SK576590A3 (en) 1999-10-08
KR910011894A (ko) 1991-08-07
JP2807093B2 (ja) 1998-09-30
NO176566C (no) 1995-04-26
LU90014I2 (fr) 1997-01-31
NO905322L (no) 1991-06-12
GB2239016B (en) 1993-08-04
AU6787690A (en) 1991-06-13
MW8890A1 (en) 1991-03-13
OA09334A (fr) 1992-09-15
MTP1075B (en) 1991-07-31
CA2030433C (en) 1997-10-21
AU634319B2 (en) 1993-02-18
IS1803B (is) 2002-02-26
GR3017114T3 (en) 1995-11-30
SG120493G (en) 1994-01-21
NL970013I1 (nl) 1997-05-01
HK129093A (en) 1993-12-03
IE904453A1 (en) 1991-06-19
ZW17490A1 (en) 1992-06-17
HU908076D0 (en) 1991-06-28
JPH03255076A (ja) 1991-11-13
CN1138983A (zh) 1997-01-01
CU22305A3 (es) 1995-01-31
EG19722A (en) 1996-01-31
EP0432695A3 (en) 1991-12-18
IL96550A (en) 1995-03-15
FI905983A0 (fi) 1990-12-04
CN1066329C (zh) 2001-05-30
IL96550A0 (en) 1991-09-16
FI905983A (fi) 1991-06-12
SI9012315A (en) 1997-10-31
HUT56073A (en) 1991-07-29
NL970013I2 (nl) 1997-09-01
IS3651A7 (is) 1991-06-12
CA2030433A1 (en) 1991-06-12
NO905322D0 (no) 1990-12-10
KR970005912B1 (en) 1997-04-22
HRP930341A2 (en) 1994-10-31
NO176566B (no) 1995-01-16
LTIP862A (en) 1995-03-27
EP0432695B1 (de) 1995-05-17
CZ576590A3 (en) 1995-11-15
ES2072959T3 (es) 1995-08-01
LT3682B (en) 1996-01-25
LV5738A4 (lv) 1996-08-20
BR9006264A (pt) 1991-09-24
SK280249B6 (sk) 1999-10-08
GB9026776D0 (en) 1991-01-30
BG51452A3 (en) 1993-05-14
CZ280558B6 (cs) 1996-02-14
DK0432695T3 (da) 1995-09-11
ZA909743B (en) 1991-08-28
LV5738B4 (lv) 1996-12-20
FI973895A0 (fi) 1997-10-06
SI9012315B (sl) 1998-06-30
FI973895A (fi) 1997-10-06
HRP930341B1 (en) 1998-12-31
PL165225B1 (pl) 1994-11-30
HU211342A9 (en) 1995-11-28
MX173630B (es) 1994-03-18
DE69019481D1 (de) 1995-06-22
GB8927913D0 (en) 1990-02-14
PT96145A (pt) 1991-09-30

Similar Documents

Publication Publication Date Title
ATE122661T1 (de) Aminosäurederivate.
MY111630A (en) Amino acid derivatives.